GPX-150: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 22 patients with metastatic and non-resectable STS showed that first-line treatment with 265 mg/m 2 IV GPX-150 every 3 weeks for up to 48 we...